Novavax Awarded $179M Contract by U.S. Govt. to Develop Flu Vaccines
March 01, 2011 at 11:29 AM EST
During a 3-year base period valued at $97 million, Novavax will continue to develop its novel, clinical-stage influenza vaccines to address the Office Biomedical Advanced Research and Develop Authority’s commitment to pandemic preparedness.